|
|
|
Volumn 15, Issue 3, 2014, Pages 278-279
|
|
MM-398 achieves primary endpoint of overall survival in phase III study in patients with gemcitabine refractory metastatic pancreatic cancer
|
|
Author keywords
Carcinoma; Drug therapy; Gemcitabine; Neoplasm metastasis; Pancreas; Pancreatic neoplasms; Therapeutics
|
|
Indexed keywords
GEMCITABINE;
IRINOTECAN SUCROSOFATE;
ANTINEOPLASTIC AGENT;
ANTINEOPLASTIC ANTIMETABOLITE;
CAMPTOTHECIN;
DEOXYCYTIDINE;
DRUG COMBINATION;
SUCROSE;
HUMAN;
NOTE;
OVERALL SURVIVAL;
PANCREAS CANCER;
PHASE 2 CLINICAL TRIAL (TOPIC);
RANDOMIZED CONTROLLED TRIAL (TOPIC);
ANALOGS AND DERIVATIVES;
CLINICAL TRIAL;
DRUG COMBINATION;
DRUG RESISTANCE;
MORTALITY;
PANCREATIC NEOPLASMS;
PHASE 3 CLINICAL TRIAL;
SECONDARY;
ANTIMETABOLITES, ANTINEOPLASTIC;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CAMPTOTHECIN;
DEOXYCYTIDINE;
DRUG COMBINATIONS;
DRUG RESISTANCE, NEOPLASM;
HUMANS;
PANCREATIC NEOPLASMS;
SUCROSE;
|
|
EID: 84901603907
PISSN: 15908577
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (15)
|
|
References (5)
|
